

Alcohol Consumption and Cardiovascular Health



Chayakrit Krittanawong, MD,^{a,b} Ameesh Isath, MBBS,^c Robert S. Rosenson, MD,^{d,e} Muzamil Khawaja, MD,^b Zhen Wang, PhD,^{d,e,f,g} Sonya E. Fogg, MLS,^h Salim S. Virani, MD, PhD,^{a,b} Lu Qi, MD, PhD,ⁱ Yin Cao, MPH, ScD,^j Michelle T. Long, MD, MSc,^k Christy C. Tangney, PhD,^l Carl J. Lavie, MD^m

^aThe Michael E. DeBakey VA Medical Center, Houston, Texas; ^bSection of Cardiology, Baylor College of Medicine, Houston, Texas; ^cDepartment of Cardiology, Westchester Medical Center, New York Medical College, Valhalla; ^dCardiometabolic Unit, Mount Sinai Hospital, Mount Sinai Heart, New York, NY; ^eMayo Clinic Evidence-based Practice Center, Rochester, Minn; ^fRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery; ^gDivision of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn; ^hLibrary and Learning Resource Center, Texas Heart Institute, Houston; ⁱDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, La; ^jDivision of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Mo; ^kSection of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Mass; ^lDepartment of Clinical Nutrition, Rush University Medical Center, Chicago, Ill; ^mJohn Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, La.

ABSTRACT

BACKGROUND: Studies evaluating alcohol consumption and cardiovascular diseases have shown inconsistent results.

METHODS: We performed a systematic review of peer-reviewed publications from an extensive query of Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception to March 2022 for all studies that reported the association between alcohol consumption in terms of quantity (daily or weekly amounts) and type of beverage (wine, beer or spirit) and cardiovascular disease events.

RESULTS: The study population included a total of 1,579,435 individuals based on 56 cohorts from several countries. We found that moderate wine consumption defined as 1-4 drinks per week was associated with a reduction in risk for cardiovascular mortality when compared with beer or spirits. However, higher risk for cardiovascular disease mortality was typically seen with heavier daily or weekly alcohol consumption across all types of beverages.

CONCLUSIONS: It is possible that the observational studies may overestimate the benefits of alcohol for cardiovascular disease outcomes. Although moderate wine consumption is probably associated with low cardiovascular disease events, there are many confounding factors, in particular, lifestyle, genetic, and socioeconomic associations with wine drinking, which likely explain much of the association with wine and reduced cardiovascular disease events. Further prospective study of alcohol and all-cause mortality, including cancer, is needed.

© 2022 Elsevier Inc. All rights reserved. • *The American Journal of Medicine* (2022) 135:1213–1230

KEYWORDS: Alcohol consumption; Beer consumption; Cardiovascular disease; Liquor consumption; Wine consumption

INTRODUCTION

The US Department of Agriculture 2015 to 2025 Dietary Guidelines for Americans¹ define moderate drinking as

having up to 1 drink per day for women and up to 2 drinks per day for men. Alcohol consumption above the recommended limits was associated with higher all-cause and

Funding: See last page of article.

Conflicts of Interest: See last page of article.

Authorship: See last page of article.

Requests for reprints should be addressed to Chayakrit Krittanawong, MD, Section of Cardiology, Baylor College of Medicine, 1 Baylor Plaza,

Houston, TX 77030. E-mail address:

E-mail address: Chayakrit.Krittanawong@bcm.edu

cause-specific mortality risk (39%-126%).² Alcohol may contain polyphenols, amino acids, and minerals,³ although the content varies considerably among types of alcohol (beer vs red wine vs white wine vs spirit). A complete understanding of these complex mechanisms in human health is limited. Several studies have shown that alcohol consumption has a J-shaped or biphasic relationship with cardiovascular disease.^{4,5} In a recent report, analyses suggest that any quantity of alcohol has a deleterious effect on cancer risk.⁴ Our study is unique in that it relies on data culled from more than 1 million individuals. We include both alcoholic beverage quantity (daily or weekly amounts) and type of beverage (wine, beer, or spirits) in relation to cardiovascular disease events. Additionally, very few meta-analyses have included spirits when the association of alcohol is examined in relation to these cardiovascular disease outcomes.

METHODS

We performed a systematic review of peer-reviewed publications from an extensive query of Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception to March 2022. Search strategy included MESH headings and keywords related to alcohol and cardiovascular disease (Supplementary Material, available online). We identified studies based on appropriate types of study (observational study, prospective cohort study, randomized controlled trial, or case control design) and the exposure (alcohol consumption). We were unable to perform meta-analysis of the results due to tremendous heterogeneity among the included studies related to intervention, comparison, outcomes, and timing. Instead, we qualitatively synthesized the results and summarized key features and characteristics (eg, study populations, design, interventions, outcomes, and conclusions) of the included studies.

RESULTS

After exclusions in our initial electronic search, we identified and reviewed a total of 56 studies related to alcohol consumption and cardiovascular outcomes. Most common adjustments were age, body mass index, hypertension, and diabetes. As for alcoholic beverages and the relationship with developing coronary artery disease, 19 total studies were included for a total of 1,009,067 individuals; 51.1% were men (Table 1). Studies were published since 1986 and included a diverse group of participants from countries all over the world. Most of the studies were prospective, but

several were case-control studies or cross-sectional. Results were variable across these cohorts, but there was a notable pattern of significantly lower hazard ratios (HRs) for coronary artery disease in low to moderate alcohol consumers (defined by weekly and daily consumption thresholds) across all categories of alcoholic beverages.

Table 2 summarizes alcohol consumption and the association with myocardial infarction (238,273 individuals). Most of these studies demonstrated a significantly lower HR for myocardial infarction in individuals with moderate to higher levels of alcohol consumption for all 3 types of beverages.

Table 3 summarizes the association between alcohol consumption and cardiovascular disease mortality (570,368 individuals with mean follow-up 11.7 years). For studies that evaluated low-moderate amounts of weekly or daily alcohol (wine, beer, or spirits) consumption, there were significantly lower risk ratios/HRs for cardiovascular disease mortality. Regardless of the specific alcoholic beverage included in the studies, the risk for cardiovascular disease mortality remained lower. Only a handful of studies noted a significantly higher risk for mortality that was associated with either heavier weekly

alcohol consumption (either wine, beer, or spirits) or a history of alcohol consumption in the past. Direct comparisons of alcoholic beverages and the effects on cardiovascular disease mortality within the same cohort showed that moderate wine consumption has a 25% reduction in risk for cardiovascular mortality when compared with beer or spirits (HR 0.75; 95% confidence interval, 0.59-0.96) (Table 3). Higher risk for cardiovascular disease mortality was typically seen with heavier daily or weekly alcohol consumption, across all types of beverages.

CLINICAL SIGNIFICANCE

- It is possible that the observational studies may overestimate the benefits of alcohol for cardiovascular disease outcomes.
- Moderate wine consumption may be associated with low cardiovascular disease events.
- There are many confounding factors, in particular, lifestyle, genetic, and socioeconomic associations with wine drinking, which likely explain much of the association with wine and reduced cardiovascular disease events.
- Further prospective study of alcohol and all-cause mortality, including cancer, is needed.

DISCUSSION

Beer Consumption and Cardiovascular Outcomes

Beer contains a wide variety of nonalcoholic components (eg, compounds derived from benzoic and cinnamic acids, catechins, procyanidins, humulones, and prenylchalcones)^{6,7} that differ from those in red wine, which has amino acids, minerals, and polyphenols (phenolic acid, prenylated chalcones, flavonoids, catechins). It also has been observed that xanthohumol inhibited the oxidation of low-density lipoprotein (LDL) in vitro induced by Cu²⁺,⁸ as well as lipid peroxidation of liver microsomes in rats.⁹

Table 1 Included Studies for Alcohol Consumption and CAD

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	OutcomeHR (95% CI)
Bos ⁶⁸	2010	Netherlands	10,530	0	Prospective	—	9.4 y	White wine	5-29.9 vs 0-4.9 g/wk	0.96 (0.76-1.21)
								White wine	30-69.9 vs 0-4.9 g/wk	1.1 (0.74-1.66)
								White wine	>70 vs 0-4.9 g/wk	0.96 (0.59-1.57)
								Red wine	5-29.9 vs 0-4.9 g/wk	0.74 (0.56-0.97)
								Red wine	30-69.9 vs 0-4.9 g/wk	0.77 (0.52-1.14)
								Red wine	>70 vs 0-4.9 g/wk	0.71 (0.43-1.16)
								Beer	5-29.9 vs 0-4.9 g/wk	1 (0.68-1.49)
								Beer	30-69.9 vs 0-4.9 g/wk	0.84 (0.49-1.43)
								Liquor	5-29.9 vs 0-4.9 g/wk	1.04 (0.76-1.41)
								Liquor	30-69.9 vs 0-4.9 g/wk	0.93 (0.61-1.41)
								Liquor	>70 vs 0-4.9 g/wk	1.17 (0.82-1.69)
								Fortified wine	5-29.9 vs 0-4.9 g/wk	1.03 (0.8-1.33)
								Fortified wine	30-69.9 vs 0-4.9 g/wk	1.01 (0.67-1.52)
								Fortified wine	>70 vs 0-4.9 g/wk	0.85 (0.6-1.19)
								White wine, red wine, beer, liquor, fortified wine	0-4.9 g/wk vs lifetime abstainer	0.98 (0.76-1.27)
								White wine, red wine, beer, liquor, fortified wine	5-29.9 g/wk vs lifetime abstainer	0.75 (0.57-0.98)
								White wine, red wine, beer, liquor, fortified wine	30-69.9 g/wk vs lifetime abstainer	0.92 (0.68-1.24)
								White wine, red wine, beer, liquor, fortified wine	70-139.9 g/wk vs lifetime abstainer	0.72 (0.52-1.01)
								White wine, red wine, beer, liquor, fortified wine	≥ 140 g/wk vs lifetime abstainer	0.65 (0.46-0.9)
								Brenner ⁶⁹	2001	Germany
Beer only	Beer only vs nondrinkers	0.5 (0.3-0.84)								
Wine only	Wine only vs nondrinkers	0.95 (0.57-1.59)								
Mixed	Mixed vs nondrinkers	0.42 (0.27-0.66)								
Wine, beer, mixed	≤ 125 g/wk vs nondrinkers	0.56 (0.36-0.86)								
Foerster ⁷⁰	2009	Switzerland	5769	2574	Cross-sectional	52.5 ± 10.6	—	Wine, beer, mixed	> 125 g/wk vs nondrinkers	0.55 (0.35-0.86)
								Wine, beer, spirits		Did not include as mean ± SE ()
Gigleux ⁷¹	2006	Canada	1966	1966	Prospective	IHD-free men - 56 ± 7	13 y	Wine, beer, spirits	≥15.2 vs <1.3 g/d	0.51 (0.33-0.8)
								Wine, beer, spirits	5.5-15.1 vs <1.3 g/d	0.81 (0.55-1.21)
Klatsky ⁷²	1986	US	85,001	37,605	Prospective cohort	—	5 y	Wine, beer, spirits	1.3-5.4 vs <1.3 g/d	0.87 (0.6-1.27)
								Wine, beer, liquor	Ex-drinkers vs abstainers	0.99 (0.72-1.36)
								Wine, beer, liquor	<1 drink/mo vs abstainers	0.93 (0.74-1.18)
								Wine, beer, liquor	<1 drink/d, >1 drink/mo vs abstainers	0.65 (0.51-0.82)
								Wine, beer, liquor	1-2 drinks/d vs abstainers	0.55 (0.42-0.72)
								Wine, beer, liquor	3-5 drinks/d vs abstainers	0.54 (0.38-0.76)
								Wine, beer, liquor	6-8 drinks/d vs abstainers	0.52 (0.26-1.05)
								Wine, beer, liquor	>9 drinks/d vs abstainers	0.47 (0.15-1.49)
Beer	Beer vs liquor	1.01 (0.69-1.46)								
Wine	Wine vs liquor	0.89 (0.64-1.24)								

Table 1 (Continued)

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	OutcomeHR (95% CI)
Klatsky ⁷³	1997	US	128,934	56,730	Prospective cohort	40.6	6 y	Red wine, beer, liquor, white wine	All drinkers (>1 drink/mo vs abstainers)	0.79 (0.71-0.88)
									<1 drink/d vs abstainers	0.93 (0.8-1.09)
									1-2 drinks/d vs abstainers	0.77 (0.65-0.91)
									≥3 drinks/d vs abstainers	0.71 (0.59-0.86)
									All drinkers (>1 drink/mo vs abstainers)	0.76 (0.65-0.89)
Marques-Vidal ⁷⁴	2004	France, Northern Ireland	9750	9750	Prospective cohort	Divided by alcohol and country	5 y	Wine, beer, spirits, cider	<1 drink/d vs abstainers	0.83 (0.7-0.98)
								Wine, beer, spirits, cider	1-2 drinks/d vs abstainers	0.64 (0.52-0.79)
								Wine, beer, spirits, cider	≥3 drinks/d vs abstainers	0.6 (0.42-0.85)
								Wine, beer, spirits, cider	0-128 mL pure ethanol/wk vs none	0.74 (0.45-1.21)
								Wine, beer, spirits, cider	128-265 mL pure ethanol/wk vs none	0.65 (0.39-1.08)
								Wine, beer, spirits, cider	265-441 mL pure ethanol/wk vs none	0.48 (0.28-0.81)
								Wine, beer, spirits, cider	≥441 mL pure ethanol/wk vs none	0.37 (0.22-0.64)
								Wine, beer, spirits, cider	0-128 mL pure ethanol/wk vs none	0.67 (0.36-1.27)
								Wine, beer, spirits, cider	128-265 mL pure ethanol/wk vs none	0.81 (0.46-1.46)
								Wine, beer, spirits, cider	265-441 mL pure ethanol/wk vs none	0.88 (0.5-1.54)
								Wine, beer, spirits, cider	≥441 mL pure ethanol/wk vs none	0.7 (0.38-1.29)
								Wine	Wine vs none	0.89 (0.82-0.98)
								Beer	Beer vs none	0.94 (0.74-1.01)
								Spirits	Spirits vs none	1.04 (0.83-1.43)
								Wine, beer, spirits, cider	Total alcohol vs none	0.96 (0.84-0.97)
								Wine	Wine vs none	0.33 (0.11-0.96)
								Beer	Beer vs none	0.99 (0.89-1.07)
								Spirits	Spirits vs none	1.03 (0.93-1.22)
								Wine, beer, spirits, cider	Total alcohol vs none	0.99 (0.92-1.06)
								Wine, beer, spirits	Alcohol vs no alcohol	1.001 (1-1.003)
Wine, beer, spirits	Drinker group 1 (<15 g/d) vs nondrinkers	0.61 (0.4-0.94)								
Wine, beer, spirits	Drinker group 2 (≥15 g/d) vs nondrinkers	0.68 (0.41-1.12)								
Wine, beer, spirits	Drinker group 1 (<15 g/d) vs lifetime abstainer	0.61 (0.39-0.95)								
Wine, beer, spirits	Drinker group 2 (≥15 g/d) vs lifetime abstainer	0.67 (0.39-1.14)								
Wine, beer, spirits	Drinker group 1 (<15 g/d) vs occasional drinker	0.71 (0.42-1.19)								
Wine, beer, spirits	Drinker group 2 (≥15 g/d) vs occasional drinker	0.75 (0.46-1.23)								
Rimm ⁷⁶	1991	US	44,059	44,059	Prospective cohort	0 g/d 0.1-5 g/d 5.1-30 g/d >30 g/d	72,290 person-years	Wine, beer, spirits	Former drinker vs lifetime abstainer	0.97 (0.56-1.71)
								Wine, beer, spirits	0.1-5 g/d vs 0 g/d	0.99 (74-1.33)
								Wine, beer, spirits	5.1-30 g/d vs 0 g/d	0.74 (0.56-0.97)
								Wine, beer, spirits	>30 g/d vs 0 g/d	0.53 (0.35-0.79)

Table 1 (Continued)

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	OutcomeHR (95% CI)
Roy ⁹⁹	2010	India	8930	8930	Cross-sectional I would delete	Alcohol users - 42.8 ± 11.0 Nonusers- 42.8 ± 11.1	—	Wine, beer, spirits	Alcohol users vs nonusers	1.4 (1-1.9)
								Wine, beer, spirits	Occasional users (less than once a week) vs nonusers	1.2 (0.8-1.6)
								Wine, beer, spirits	Regular users (once or more in a week) vs nonusers	1.6 (1-2.2)
								Wine, beer, spirits	Past users (quit at least 6 months ago) vs nonusers	2.1 (1.1-3)
								Local spirits	Local spirits vs none	1.8 (1-2.6)
								Branded spirits	Branded spirits vs none	1.5 (0.9-2.2)
								Wine, beer, spirits	<14 g/d vs no alcohol	1.3 (1.2-1.5)
								Wine, beer, spirits	14-28 g/d vs no alcohol	1.6 (1-2.3)
								Wine, beer, spirits	>28 g/d vs no alcohol	2 (1.2-2.6)
								Schutte ¹¹¹	2020	UK
Champagne/white wine	Champagne/white wine vs other alcohol drinkers	0.84 (0.72-0.98)								
Red wine	Red wine vs other alcohol drinkers	0.88 (0.77-0.99)								
Spirits	Spirits vs other alcohol drinkers	1.17 (1.02-1.35)								
Wine, beer, spirits	0.65-5.77 g vs <0.65 g/d	1.66 (0.2-13.92)								
Wine, beer, spirits	5.78-18.1 g vs <0.65 g/d	0.57 (0.06-5.52)								
Snow ¹⁰⁰	2009	Canada	1154	580	Prospective cohort	—	10 y	Wine, beer, spirits	>18.1 vs <0.65 g/d	0.44 (0.04-4.59)
								Wine, beer, spirits	>18.1 (heavy) episodic vs <0.65 g/d	4.13 (1.46-11.62)
								Wine, beer, spirits	0.65-5.77 g vs <0.65 g/d	0.98 (0.4-2.37)
								Wine, beer, spirits	5.78-18.1 g vs <0.65 g/d	0.75 (0.29-1.95)
								Wine, beer, spirits	>18.1 vs <0.65 g/d	0.28 (0.08-0.93)
								Wine, beer, spirits	>18.1 (heavy) episodic vs <0.65 g/d	1.76 (0.81-3.82)
								Wine, beer, spirits	0.65-2.92 g vs <0.65 g/d	1.13 (0.07-18.39)
								Wine, beer, spirits	2.93-9.15 g vs <0.65 g/d	2.95 (0.29-29.69)
								Wine, beer, spirits	>9.15 g vs <0.65 g/d	1.96 (0.17-22.19)
								Wine, beer, spirits	>9.15 g (heavy) episodic vs <0.65 g/d	1.09 (0.99-1.19)
								Wine, beer, spirits	0.65-2.92 g vs <0.65 g/d	1.35 (0.51-3.57)
								Wine, beer, spirits	2.93-9.15 g vs <0.65 g/d	2.12 (0.82-5.48)
								Wine, beer, spirits	>9.15 g vs <0.65 g/d	0.44 (0.09-2.02)
								Wine, beer, spirits	>9.15 g (heavy) episodic vs <0.65 g/d	0 (0-∞)
Song ¹⁰¹	2018	US	156,728	142,622	Prospective cohort	65.3 ± 12.1	2.9 y	Wine, beer, spirits	Former drinkers vs never drinkers	1.02 (0.92-1.13)
								Wine, beer, spirits	≤6 g/d vs never drinkers	0.83 (0.74-0.93)
								Wine, beer, spirits	>6-12g/d vs never drinkers	0.77 (0.67-0.87)
								Wine, beer, spirits	>12-24g/d vs never drinkers	0.71 (0.62-0.81)
								Wine, beer, spirits	>24-36g/d vs never drinkers	0.62 (0.51-0.76)
								Wine, beer, spirits	>36-48 g/d vs never drinkers	0.58 (0.46-0.74)
Stampfer ⁷⁷	1988	US	87,526	0	Prospective cohort	34-59	334,382 person-years	Wine, beer, spirits	<1.5 g/d vs 0 g/d	0.7 (0.5-1.1)
								Wine, beer, spirits	1.5-4.9 g/d vs 0 g/d	0.5 (0.4-0.8)
								Wine, beer, spirits	5-14.9 g/d vs 0 g/d	0.5 (0.4-0.8)
								Wine, beer, spirits	15-24.9 g/d vs 0 g/d	0.6 (0.3-1.1)
								Wine, beer, spirits	>25 g/d vs 0 g/d	0.6 (0.3-1)
								Wine, beer, spirits	>25 g/d vs 0 g/d	0.6 (0.3-1)

Table 1 (Continued)

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	OutcomeHR (95% CI)
Wannamethee ⁷⁸	1999	UK	7272	7272	Prospective cohort	40-59	16.8 y	Wine, beer, spirits	None vs occasional (<1 unit per week)	1.03 (0.78-1.37)
								Wine, beer, spirits	Light (1-15 units per week) vs occasional	0.76 (0.64-0.91)
								Wine, beer, spirits	Moderate (16-42 units per week), vs occasional	0.78 (0.65-0.94)
								Wine, beer, spirits	Heavy (more than 6 units per day) vs occasional	0.75 (0.59-0.95)
								Beer	Regular drinker vs occasional drinker	0.78 (0.63-0.97)
								Spirits	Regular drinker vs occasional drinker	0.57 (0.39-0.85)
								Beer and spirits	Regular drinker vs occasional drinker	0.75 (0.5-1.1)
								Wine	Regular drinker vs occasional drinker	0.92 (0.51-1.67)
								Wine/sherry, beer, spirits	Regular drinker vs occasional drinker	1.23 (0.54-2.79)
								Spirits, beer	Spirits vs beer in occasional and regular drinkers	1.07 (0.9-1.26)
Wellmann ⁷⁹	2004	Germany	2710	1345	Prospective cohort	35-64	10 y in men 10.1 in women	Wine, beer, spirits	0.1-19.9 g/d vs 0 g/d	0.34 (0.17-0.69)
									20.0-39.9 g/d vs 0 g/d	0.43 (0.22-0.81)
									40.0-79.9 g/d vs 0 g/d	0.7 (0.4-1.22)
									>80.0 g/d vs 0 g/d	0.33 (0.12-0.89)
									Quitter vs nondrinker	0.78 (0.32-1.87)
									Starter vs nondrinker	0.32 (0.09-1.18)
									Constant drinker 0.1-19.9 g/d vs nondrinker	0.29 (0.12-0.7)
									Constant drinker 20.0-39.9 g/d vs nondrinker	0.39 (0.17-0.87)
									Constant drinker 40.0-79.9 g/d vs nondrinker	0.6 (0.29-1.24)
									Constant drinker >80.0g/d vs nondrinker	0.29 (0.1-0.86)
Woodward ⁸⁰	1995	Scotland			Cross-sectional	40-59	-	Wine, beer, spirits	1-7 Units/wk vs 0	0.99 (0.7-1.41)
									8-15 Units/wk vs 0	0.99 (0.69-1.42)
									16-29 Units/wk vs 0	0.97 (0.66-1.43)
									>30 Units/wk vs 0	1.04 (0.67-1.61)
									1-2 Units/wk vs 0	0.57 (0.36-0.91)
									3-5 Units/wk vs 0	0.62 (0.41-0.96)
									6-9 Units/wk vs 0	0.74 (0.47-1.15)
>10 Units/wk vs 0	0.61 (0.37-1.01)									
Keil ⁸¹	1997	Germany	2087	1074	Prospective cohort	45-64	7.9 y	Beer	Drinkers vs nondrinkers	0.55 (0.29-1.02)
									0.1-19.9 g/d vs nondrinkers	0.54 (0.24-1.2)
									20-39.9 g/d vs nondrinkers	0.48 (0.21-1.09)
									40-79.9 g/d vs nondrinkers	0.63 (0.3-1.29)
Biddinger ⁸²	2022	UK	371,463	172,400	Cohort	57.0 ± 7.9	~ 6 y	Wine, beer, spirits	>80 g/d vs nondrinkers	0.48 (0.18-1.28)
									Light drinkers vs none	1.7 (1.2- 2.3)
									Moderate drinkers vs none	1.7 (1.1-2.7)
									Heavy drinkers vs none	2.1 (1.1- 3.9)
								Abuse drinkers vs none	5.7 (2.4-13.5)	

AUD = alcohol use disorder; CAD = coronary artery disease; IHD = ischemic heart disease; CI - Confidence interval.

Table 2 Included Studies for Alcohol Consumption and Myocardial Infarction

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	OutcomesHR (95% CI)
Gigleux ⁷¹	2006	Canada	1966	1966	Prospective	—	13 y	Wine, beer, spirits	≥15.2 vs <1.3 g/d 5.5-15.1 vs <1.3 g/d 1.3-5.4 vs <1.3 g/d	0.51 (0.33-0.8) 0.81 (0.55-1.21) 0.87 (0.6-1.27)
Klatsky ⁷²	1986	US	85,001	37,605	Prospective cohort	—	5 y	Wine, beer, spirits	Ex-drinkers vs abstainers <1 drink/mo vs abstainers < 1 drink/d, > 1 drink/mo vs abstainers 1-2 drinks/d vs abstainers 3-5 drinks/d vs abstainers 6-8 drinks/d vs abstainers >9 drinks/d vs abstainers	1.19 (NR-NR) 0.97 (NR-NR) 0.72 (NR-NR) 0.54 (NR-NR) 0.38 (NR-NR) 0.7 (NR-NR) 0.31 (NR-NR)
Marques-Vidal ⁷⁴	2004	France, Northern Ireland	9750	9750	Prospective cohort	—	5 y	Wine, beer, spirits, cider	0-128 mL pure ethanol/wk vs none 128-265 mL pure ethanol/wk vs none 265-441 mL pure ethanol/wk vs none ≥ 441 mL pure ethanol/wk vs none 0-128 mL pure ethanol/wk vs none 128-265 mL pure ethanol/wk vs none 265-441 mL pure ethanol/wk vs none ≥441 mL pure ethanol/wk vs none Wine vs none Beer vs none Spirits vs none Wine, beer, spirits, cider Wine vs none Beer vs none Spirits vs none Wine, beer, spirits, cider Total alcohol vs none	0.54 (0.29-1.02) 0.45 (0.23-0.87) 0.37 (0.19-0.73) 0.26 (0.13-0.54) 0.62 (0.27-1.45) 0.69 (0.31-1.52) 0.56 (0.25-1.28) 0.43 (0.17-1.09) 0.88 (0.78-1) 0.89 (0.58-0.99) 1.09 (0.95-1.58) 0.95 (0.8-0.98) 0.18 (0.03-1.29) 0.97 (0.81-1.08) 1.01 (0.84-1.26) 0.98 (0.85-1.06)
Park ⁷⁵	2017	Korea	8330	3936	Prospective cohort	40-49 y, n = 3876 (46.5%) 50-59 y, n = 2220 (26.7%) 60-69 y, n = 2234 (26.8%)	10 y	Wine, beer, spirits	Drinker group 1 (<15 g/d) vs nondrinkers Drinker group 2 (≥15 g/d) vs nondrinkers Drinker group 1 (<15 g/d) vs lifetime abstainer Drinker group 2 (≥15 g/d) vs lifetime abstainer Drinker group 1 (<15 g/d) vs occasional drinker Drinker group 2 (≥15 g/d) vs occasional drinker Former drinker vs lifetime abstainer	0.44 (0.21-0.92) 0.42 (0.19-0.93) 0.41 (0.19-0.9) 0.39 (0.16-0.91) 0.65 (0.29-1.45) 0.51 (0.23-1.12) 0.84 (0.35-1.98)
Rimm ⁵⁷	1991	US	44,059	44,059	Prospective cohort	0 g/d 0.1-5 g/d 5.1-30 g/d >30 g/d	72,290 person-years	Wine, beer, spirits	0.1-5 g/d vs 0 g/d 5.1-30 g/d vs 0 g/d >30 g/d vs 0 g/d	0.99 (0.65-1.51) 0.71 (0.47-1.06) 0.65 (0.37-1.31)
Stampfer ⁷⁷	1988	US	87,526	0	Prospective cohort	34-59	334,382 person-years	Wine, beer, spirits	<1.5 g/d vs 0 g/d 1.5-4.9 g/d vs 0 g/d 5-14.9 g/d vs 0 g/d 15-24.9 g/d vs 0 g/d >25 g/d vs 0 g/d	0.7 (0.5-1.1) 0.5 (0.4-0.8) 0.5 (0.4-0.8) 0.6 (0.3-1.1) 0.6 (0.3-1)
Kauhanen ⁹³	1997	Finland	1641	1641	Prospective cohort	6 or more 50.4 (6.0) 3-5 51.2 (5.6) <3 52.4 (5.0)	7.7 y	Beer Beer	6 or more vs <3 bottles 3-5 bottles vs <3 bottles	0.96 (0.39-2.35) 1.28 (0.85-1.93)
Biddinger ⁶²	2022	UK	371,463	172,400	Cohort	57.0 ± 7.9	~ 6 y	Wine, beer, spirits	Light drinkers vs none Moderate drinkers vs none Heavy drinkers vs none Abuse drinkers vs none	1.3 (0.89- 2.11) 2.6 (1.39- 4.94) 1.8 (0.78- 4.30) 7.3 (2.28-23.84)

Table 3 Included Studies for Alcohol Consumption and Cardiovascular Mortality

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	Outcome HR (95% CI)
Behrens ⁸³	2011	Sweden	49,259	0	Prospective	—	713,295 person-years	Wine, beer, spirits	0.1-1.4 g/d vs 0 g/d	0.76 (0.48-1.2)
									1.5-4.9 g/d vs 0 g/d	0.57 (0.36-0.91)
									5.0-9.9 g/d vs 0 g/d	0.85 (0.52-1.38)
									10.0+ g/d vs 0 g/d	0.55 (0.27-1.12)
Berberian ⁸⁴	1994	Netherlands	1620	760	Prospective survey based	—	10 y	Wine, beer, spirits	0.1-19.9g/d vs 0 g/d	0.69 (0.46-1.01)
									Occasional (<1 time a week) vs no drinks and ex-drinkers	0.23 (0.07-0.73)
									Frequent (one time a week or more) vs no drinks and ex-drinkers	0.61 (0.26-1.38)
Bertoia ⁸⁵	2012	US	93,676	0	Prospective	—	3 y	Wine, beer, spirits	Daily alcohol vs no drinks and ex-drinkers	0.37 (0.13-1)
									Never drinker vs 0.1-5 g	1.85 (0.86-3.98)
									Former drinker vs 0.1-5 g	0.92 (0.47-1.81)
Dai ⁸⁶	2015	US	843	843	Prospective	48 ± 3.1	41 y	Wine, beer, spirits	5.1-10 g vs 0.1-5 g	0.64 (0.38-1.1)
									10.1-30 g vs 0.1-5 g	0.86 (0.55-1.32)
									>30 g vs 0.1-5 g	0.83 (0.42-1.64)
									Per 10-g increment in alcohol intake	0.97 (0.94-1.01)
Deev ⁸⁷	1998	Russia, US	8164	3808	Prospective	—	13 y	Wine, beer, spirits	Had at least 1 drink last year but none last week vs nondrinker	0.76 (0.47-1.22)
									0 < g last week ≤ 12 vs nondrinker	0.54 (0.35-0.84)
									12 < g last week ≤ 24 vs nondrinker	0.39 (0.23-0.67)
									> 24 g last week vs nondrinker	0.48 (0.3-0.77)
									Had at least 1 drink last year but none last week vs nondrinker	0.76 (0.48-1.18)
									0 < g last week ≤ 12 vs nondrinker	0.79 (0.51-1.21)
									12 < g last week ≤ 24 vs nondrinker	0.68 (0.42-1.11)
									> 24 g last week vs nondrinker	0.98 (0.62-1.56)
									Had at least 1 drink last year but none last week vs nondrinker	0.51 (0.31-0.82)
									0 < g last week ≤ 6 vs nondrinker	0.45 (0.27-0.75)
> 6 g last week vs nondrinker	0.38 (0.23-0.62)									
Diem ⁸⁸	2003	Switzerland	287	162	Prospective	46.2 ± 5.9	12.6 ± 0.6 y	Wine, beer, spirits	Had at least 1 drink last year but none last week vs nondrinker	0.78 (0.53-1.14)
									0 < g last week ≤ 6 vs nondrinker	0.63 (0.37-1.06)
									> 6 g last week vs nondrinker	1.2 (0.54-2.65)
									1-15 g/d vs 0 g/d	0.87 (0.25-2.52)
Grabas ⁸⁹	2016	Netherlands	1919	1599	Prospective	67.0 [IQR 12.5]	2.2 y [IQR 2.0]	Wine, beer, spirits	16-30 g/d vs 0 g/d	0 (0-0.92)
									>30 g/d vs 0 g/d	0.37 (0.01-2.42)
									0 units/wk vs 1-14 units/wk	1.42 (0.84-2.38)
									15-21 units/wk vs 1-14 units/wk	1.63 (0.8-3.29)
								>21 units/wk vs 1-14 units/wk	1.7 (0.94-3.06)	

Table 3 (Continued)

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	Outcome HR (95% CI)
Harriss ⁹⁰	2007	Australia	38,200	15,156	Prospective cohort	40-69; grouped by sex and drinking	11.4 y	Wine, beer, spirits	Former drinkers vs lifetime abstainers	2.58 (1.51-4.41)
									Occasional drinkers (<10 g/wk) vs lifetime abstainers	1.65 (0.92-2.96)
									1.43-20 g/d vs lifetime abstainers	1.39 (0.92-2.09)
									>20-40 g/d vs lifetime abstainers	1.01 (0.63-1.63)
									>40 g/d vs lifetime abstainers	1.27 (0.79-2.04)
									Former drinkers vs lifetime abstainers	1.25 (0.57-2.74)
									Occasional drinkers (<10 g/wk) vs lifetime abstainers	1.07 (0.6-1.89)
									1.43-20 g/d vs lifetime abstainers	0.82 (0.5-1.34)
									>20-40 g/d vs lifetime abstainers	1.03 (0.62-1.72)
									>40 g/d vs lifetime abstainers	0.43 (0.19-0.95)
Hernandez-Hernandez ⁹¹	2015	Spain	14651	—	Prospective cohort	No total cohort mean age; grouped by drinking	9.7 y	Wine, beer, spirits	Abstainers vs MADP score high (7-9)	1.91 (0.52-6.98)
									MADP score	3.35 (0.77-14.5)
									Low (0-2) vs high (7-9)	
									MADP score	2.64 (1.11-6.23)
									Low (0-2) vs high (7-9)	
									Alcohol intake low vs moderate	1.53 (0.64-3.81)
									Alcohol intake high vs moderate	3.24 (0.93-11.65)
									Regular vs distributed	1.07 (0.39-2.88)
									Concentrated vs distributed	0.50 (0.15-1.68)
									Yes vs no	1.62 (0.65-4.12)
No vs yes	1.08 (0.46-2.62)									
With meals, no vs yes	1.40 (0.62-3.27)									
No vs yes	0.89 (0.43-1.91)									
Excess vs no excess	1.68 (0.73-4.08)									
Hoffmeister ⁹²	1999	Germany	15,400	7677	Prospective cohort	25-69	6.9 y	Wine, beer, spirits	1-20 vs 0 g/d	0.42 (0.2-9)
									21-40 vs 0 g/d	0.72 (0.34-1.53)
									40-80 vs 0 g/d	0.73 (0.31-1.74)
									>80 vs 0 g/d	0.35 (0.05-2.67)
									1-20 vs 0 g/d	0.68 (0.25-1.86)
									21-40 vs 0 g/d	1.62 (0.51-5.16)
									40-80 vs 0 g/d	1.38 (0.3-6.28)
Kauhanen ⁹³	1997	Finland	1641	1641	Prospective cohort	6 or more 50.4 (6.0) 3-5 51.2 (5.6) <3 (reference group) 52.4 (5.0)	7.7 y	Beer	6 or more vs <3 bottles	7.05 (1.93-25.67)
									3-5 bottles vs <3 bottles	2.4 (0.95-6.06)
Laatikainen ⁹⁴	2003	Finland	5092	5092	Prospective cohort	Drinkers with heavy pattern - 42.1 (10.5) No heavy drinking occasions - 45.5 (11.2)	7.3 y	Wine, beer, spirits	Heavy drinkers vs other drinkers	1.77 (1.01-3.08)

Table 3 (Continued)

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	Outcome HR (95% CI)
Malyutina ⁹⁶	2002	Russia	6502	6502	Prospective cohort	25-64	9.5 y	Wine, beer, spirits	Nondrinkers vs none	1.55 (1.16-2.09)
									<40 g vs none	0.71 (0.42-1.22)
									40-79 g vs none	0.78 (0.53-1.15)
									80-119 g vs none	0.85 (0.57-1.27)
									120-159 g vs none	1.25 (0.81-1.95)
Mukamal ⁹⁵	2010	US	10670	—	Prospective cohort	—	5 y	Wine, beer, spirits	≥160 g vs none	0.91 (0.65-1.29)
									Lifelong infrequent drinker vs never drinker	0.96 (0.89-1.03)
									Former drinker vs never drinker	1.02 (0.94-1.11)
									Light (≤3 drinks/wk) vs never drinker	0.71 (0.61-0.83)
									Moderate (>3–7 drinks/wk for women and >3–14 drinks/wk for men) vs never drinker	0.65 (0.53-0.79)
Mukamal ⁹⁷	2001	US	1913	1318	Prospective cohort	Abstainers - 65 (12) <7 - 60 (12) >7 - 57 (12)	3.8 y	Wine, beer, spirits	<7 drinks/wk vs abstainers	0.75 (0.55-1.02)
									≥7 drinks/wk vs abstainers	0.67 (0.41-1.17)
Pai ⁹⁸	2012	US	1818	1818	Prospective cohort	40-75	20 y	Wine, beer, spirits	0.1-9.9 g/d vs 0 g/d	0.74 (0.54-1.02)
Renaud ¹¹⁴	2004	Europe	36,583		Prospective cohort	Abstainers 47.98 ± 5.692 Wine drinkers 48.39 ± 5.69 Other drinkers 47.28 ± 5.55	13-21 y	Wine	10.0-29.9 g/d vs 0 g/d	0.58 (0.39-0.84)
									≥30.0 g/d vs 0 g/d	0.98 (0.6-1.6)
									Moderate wine drinkers (<60 g alcohol/d and no beer) vs abstainers	0.755 (0.591-0.965)
									Wine drinkers of ≥60 g/d vs abstainers	0.971 (0.748-1.261)
Renaud ¹¹³	1998	Europe	34,014	34014	Prospective cohort	48.87	418,068 person-years	Wine, beer, spirits	Moderate other drinkers (<60 g alcohol/d) vs abstainers	0.853 (0.631-1.153)
									Other drinkers of ≥60 g/d vs abstainers	0.951 (0.729-1.241)
									1-21 g/d vs 0-Occasionally	0.83 (0.55-1.25)
									22-32 g/d vs 0-Occasionally	0.65 (0.45-0.95)
									33-54 g/d vs 0-Occasionally	0.72 (0.52-1)
Rimm ¹¹²	1991	US	44,059	44059	Prospective cohort	0 g/d 0.1-5 g/d 5.1-30 g/d >30 g/d	72,290 person-years	Wine, beer, spirits	55-76 g/d vs 0-Occasionally	0.73 (0.48-1.1)
									77-128 g/d vs 0-Occasionally	0.67 (0.48-0.94)
									>128 g/d vs 0-Occasionally	0.75 (0.48-1.18)
									0.1-5 g/d vs 0 g/d	1.1 (0.52-2.36)
Stampfer ⁷⁷	1988	US	87,526	0	prospective cohort	34-59	334,382 person-years	Wine, beer, spirits	5.1-30 g/d vs 0 g/d	0.71 (0.34-1.49)
									>30 g/d vs 0 g/d	0.66 (0.24-1.82)
									<1.5 g/d vs 0 g/d	0.7 (0.2-1.7)
									1.5-4.9 g/d vs 0 g/d	0.2 (0.1-0.6)
									5-14.9 g/d vs 0 g/d	0.3 (0.1-0.9)
15-24.9 g/d vs 0 g/d	0.2 (0.03-1.2)									
>25 g/d vs 0 g/d	0.6 (0.2-1.9)									

Table 3 (Continued)

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	Outcome HR (95% CI)
Streppel ¹¹⁰	2009	Netherlands	1373	1373	Prospective cohort	49 ± 6	40 y	Wine, beer, spirits	>0 to 20 g/d vs 0	0.7 (0.55-0.89)
									>20 g/d vs 0	0.83 (0.56-1.22)
									>0 to 20 g/d vs 0	0.92 (0.58-1.46)
									>0 to 20 g/d vs 0	0.81 (0.48-1.35)
									>20 g/d vs 0	0.78 (0.09-6.73)
									>0 to 20 g/d vs 0	1.44 (0.72-2.86)
Suhonen ¹⁰⁹	1987	Finland	4532	4532	Prospective cohort	40-64	2 y for SCD (5 y total)	Wine, beer, spirits	Alcohol consumers vs abstainers	2.5 (1.1-5.9)
									Theobald ¹⁰⁸	2000
Beer vs no beer drinker	1.15 (0.67-1.99)									
Spirits vs no spirits drinker	0.88 (0.48-1.59)									
Ex-drinkers vs 1-49 gram/wk	3.05 (1.37-6.77)									
Lifelong abstainers vs 1-49 g/wk	1.09 (0.48-2.48)									
50-139 g/wk vs 1-49 g/wk	1.39 (0.8-2.42)									
Trevisan ¹⁰⁷	2001	Italy	15,649	8980	Prospective cohort	30-59	7 y	Wine	140+ g/wk vs 1-49 g/wk	1.77 (0.77-4.08)
									Wine with meals vs Nondrinkers	0.5 (0.33-0.74)
									Wine outside meals vs Nondrinkers	0.81 (0.45-1.43)
									Wine + liquor vs Nondrinkers	0.62 (0.38-1.03)
Tverdal ¹⁰⁶	2017	Norway	115,592	53,819	Prospective cohort	40-44	16 y	Wine, beer, spirits	Men - 0, not teetotal vs teetotal	0.53 (0.37-0.77)
									Men - >0-<0.5 units/d vs teetotal	0.43 (0.29-0.63)
									Men - 0.5-<1.0 units/d vs teetotal	0.4 (0.28-0.59)
									Men - 1.0-<1.5 units/d vs teetotal	0.48 (0.32-0.71)
									Men - 1.5-<2.0 units/d vs teetotal	0.46 (0.3-0.71)
									Men - 2.0-<3.0 units/d vs teetotal	0.38 (0.23-0.62)
									Men - 3.0-<4.0 units/d vs Teetotal	0.51 (0.27-0.95)
									Men - 4.0+ units/d vs teetotal	0.48 (0.23-1)
									Women - 0, not teetotal vs teetotal	0.63 (0.38-1.06)
									Women - >0-<0.5 units/d vs teetotal	0.54 (0.31-0.94)
									Women - 0.5-<1.0 units/d vs teetotal	0.61 (0.34-1.09)
									Women - 1.0-<1.5 units/d vs teetotal	0.61 (0.29-1.32)
									Women - 1.5-<2.0 units/d vs teetotal	0.4 (0.14-1.18)
									Women - 2.0-<3.0 units/d vs teetotal	0.23 (0.03-1.72)
									Women - 3.0-<4.0 units/d vs teetotal	0.85 (0.11-6.39)

Table 3 (Continued)

First Author	Year	Country	Number of Participants	Men	Type of Study	Age, Years	Follow-Up	Type of Drink	Comparison	Outcome HR (95% CI)									
Waškiewicz ¹⁰⁵	2004	Poland	5352	2686	Prospective cohort	Male	56,261.9 person-years	Wine, beer, spirits	1 tertile (mean alcohol intake - 1.1 g/d) vs abstainers	0.584 (0.369-0.924)									
									2 tertile (mean alcohol intake - 3.9 g/d) vs abstainers	0.588 (0.366-0.944)									
									3 tertile (mean alcohol intake - 28.2 g/d) vs abstainers	0.6 (0.364-0.989)									
									Female	1 tertile (mean alcohol intake - 0.2 g/d) vs abstainers	0.581 (0.339-0.996)								
										2 tertile (mean alcohol intake - 0.4 g/d) vs abstainers	0.432 (0.228-0.817)								
										3 tertile (mean alcohol intake - 2.8 g/d) vs abstainers	0.329 (0.135-0.804)								
									Yuan ¹⁰⁴	1997	China	18,244	18,244	Prospective cohort	45-64	6.7 y	Wine, beer, spirits	1-28 drinks/wk vs nondrinkers	0.64 (0.41-0.998)
																		>28 drinks/wk vs nondrinkers	0.88 (NR-NR)
									Hart ¹⁰³	1999	Sweden	5766	5766	Prospective cohort	35-64	5141 person-years	Wine, beer, spirits	1-7 units/wk vs none	1.13 (0.9-1.42)
8-14 units/wk vs none	0.79 (0.61-1.01)																		
15-21 units/wk vs none	1.06 (0.81-1.38)																		
22-34 units/wk vs none	1.01 (0.77-1.34)																		
≥35 units/wk vs none	1 (0.75-1.35)																		
Suadicani ¹⁰²	2008	Denmark	3022	3022	Prospective cohort	63 y (range, 53-74)	16 y	Wine	1-8 drinks/wk vs 0 drinks of wine/wk	0.7 (0.5-0.98)									
									>8 drinks/wk vs 0 drinks of wine/wk	0.9 (0.6-1.2)									
									1-8 drinks/wk vs alcohol abstainers	0.6 (0.4-0.96)									
									>8 drinks/wk vs alcohol abstainers	0.7 (0.5-1.2)									
Wannamethee ⁷⁸	1999	UK	7272	7272	Prospective cohort	40-59	16.8 y	Spirits, beer	Spirits vs beer in occasional and regular drinkers	1.02 (0.83-1.25)									
									Wine vs beer in occasional and regular drinkers	0.71 (0.52-0.98)									

IQR = interquartile range; MADP = Mediterranean alcohol-drinking pattern; SCD = Sudden Coronary Death; CI - Confidence interval .

Moderate beer consumption (1 drink/d for women and 1-2 drinks/d for men) perhaps reduces cardiovascular risks due to a mechanism of prevention of LDL oxidation and induction of cholesterol efflux from macrophages, a process considered a first step in the reverse cholesterol transport pathway.^{10,11} Beer can also influence high-density lipoprotein (HDL)-induced cholesterol efflux, increase ABCA1-mediated cholesterol efflux,¹² enhance the antioxidant capacity of HDL, elevate plasma HDL cholesterol (HDL-c) levels,^{13,14} and acutely improve arterial properties.¹⁵ Non-alcoholic-related beer components protect against hyperlipidemia-induced coronary endothelial dysfunction by counteracting vascular oxidative damage and preserving the Akt/endothelial nitric oxide synthase pathway.¹⁶ The anti-inflammatory mechanisms of the bioactive compounds of beer are mainly due to the inhibition of inducible nitric oxide synthase and the inhibition of the activity of cyclooxygenase 1.^{6,17}

One study reported that low-moderate beer consumption is associated with HDL efflux capacity.¹⁸ In a randomized control trial, moderate beer consumption for 4 weeks raised HDL-c levels by a mean of 2.2 mg/dL in individuals with an LDL-c <130 mg/dL;¹⁹ circulating HDL quality was improved already in the 4-week period by rendering HDL particles functionally active to prevent LDL oxidation and facilitate cell-cholesterol efflux. However, regular beer intake increased the plasma gamma-glutamyl transferase levels in 15% of subjects because beer is primarily metabolized in the liver using enzyme alcohol dehydrogenase,²⁰ and therefore, patients with liver disease or at risk for liver injury (eg, those with nonalcoholic fatty liver disease or chronic hepatitis) should avoid beer consumption. One meta-analysis demonstrated that alcohol is a major risk factor for liver cirrhosis, with risk increasing exponentially.²¹ Moreover, women may be at higher risk compared with men, even with little alcohol consumption. Additionally, alcohol consumption has a causal association with cancers of the oral cavity, pharynx, larynx, esophagus, lungs, liver, colon, rectum, and, in women, the breast. However, some studies did not find the association between alcohol consumption and cancers.

Wine Consumption and Cardiovascular Outcomes

Wine can be classified into white wine and red wine for evaluation in studies and because of different mechanisms for cardioprotective benefits. In the 1980s, the French paradox was observed due to low cardiovascular disease mortality (primarily from coronary artery disease) despite high intake of dietary cholesterol and saturated fat.^{22,23} There was also the indirect observation that the French population consumed red wine with their diet, which was mostly high in saturated fat, and this correlation between wine and cardiovascular disease protection was attributed to the consumption of red wine.²⁴ Red wine primarily contains polyphenols, which are a combination of both flavonoids

(eg, anthocyanins and flavan-3-ols) and nonflavonoids (eg, resveratrol, cinnamates, and gallic acid). In fact, flavonoids such as Flavan-3-ols are the most abundant and contain up to 50% of the total phenolic constituents.²⁵ Wine promotes cardiovascular health via multiple mechanisms. These include polyphenols lowering plasma concentrations of pro-oxidant and inflammatory molecules and leukocyte adhesion molecules, improving homeostasis model assessment of insulin resistance values and blood pressure, reducing phospholipids oxidation, modulating cell signaling pathways, reducing platelet aggregation,²⁶⁻²⁸ decreasing highly sensitive C-reactive protein, as well as concentrations of monocyte and endothelial adhesion molecules.^{29,30} St Leger et al³¹ reported a negative correlation between alcohol consumption and ischemic heart disease deaths, and attributed this observation predominantly to wine. Several explanations for the French paradox have been postulated,²⁴ with epidemiologists presenting strong correlations in favor of wine (both white and red), with other scientific literature criticizing these observations. Compared with beer or spirits, consumption of wine has been independently associated with improvements in heart rate variability, a marker of autonomic balance.³² In the CASCADE trial, in individuals with slow ethanol metabolizers (alcohol dehydrogenase alleles carriers *ADH1B*1*), wine consumption is associated with better glycemic control (eg, fasting plasma glucose, homeostatic model assessment of insulin resistance, and hemoglobin A1c) compared with individuals with fast ethanol metabolizers (homozygous *ADH1B*2*).³³ Indeed, studies on wine consumption and cardiovascular disease are primarily based on observational studies. There is the risk of bias from confounding factors (eg, socioeconomic status, neighborhood, culture, physical activity, exercise) or unmeasured confounding (eg, genetics, gut microbiome).

Red Wine Consumption and Cardiovascular Outcomes

Compared with white wine, red wine has an approximately 10-fold higher polyphenolic content due to red wine's grape fermentation.³⁴ Unfortunately, few studies directly compare the different effects on cardiovascular health of red wine vs white wine.

Red wine promotes cardiovascular health via mechanisms of polyphenols, improved endothelial function, and increased circulating endothelial progenitor cells and nitric oxide levels.³⁵ Red wine has higher levels of bioflavonoids (with antioxidant, antiplatelet, and antiendothelin-1 effects),³⁶ polyphenolic mixtures such as flavonoids (eg, catechin/epicatechin/quercetin, procyanidins, and anthocyanins), polymeric tannins, and resveratrol (eg, 3,5,4'-trihydroxystilbene).³⁷ In general, red wine contains abundant polyphenols and is, perhaps, considered a crucial polyphenol source in the diet.³⁸ Red wine may be associated with increased HDL-c,^{39,40} improved insulin resistance^{28,41} and oxidative stress,^{42,43} and downregulated serum

concentrations of CD40 antigen, CD40 ligand, interleukin-16, monocyte chemoattractant protein-1, and vascular cell adhesion molecule-1.²⁶ It also can reduce the propensity of LDL to undergo lipid peroxidation.⁴⁴ In addition, a recent study found that people who drank red wine had increased gut microbiota diversity (a sign of gut health) compared with non-red-wine drinkers, as well as an association with lower levels of obesity and “bad” cholesterol.⁴⁵

Although alcohol increases triglyceride levels, very low-density lipoprotein production, and triglyceride enrichment of HDL, little is known about alcohol’s effect on lipoprotein (a). In the CASCADE trial, 224 abstainers with type 2 diabetes were randomized to consume red wine, white wine, or mineral water for 2 years.³³ This long-term randomized controlled trial among well-controlled diabetics found that initiating moderate red wine is associated with increased HDL-c levels by 2.0 mg/dL and decreased the total cholesterol-to-HDL-c ratio by 27%. Moreover, red wine is associated with a reduction in components of the metabolic syndrome by 34%, compared with the changes in the water group. In fact, some studies performed in women observed that daily doses of 15-20 g of alcohol such as red wine were sufficient to elicit anti-inflammatory effects similar to those observed in men who consumed higher doses of wine.⁴⁶

White Wine Consumption and Cardiovascular Outcomes

Compared with red wine, studies in white wine are inconclusive, and its mechanism for cardiovascular benefits is unclear. Clinical trials have suggested that white wine, particularly aged white wine, could promote cardiovascular health via various mechanisms. These include repair and maintenance of endothelial integrity, antioxidative and anti-atherogenic effects, an increase in HDL-c, increase in para-oxonase-1 and glutathione peroxidase, reduced glutathione levels, a decrease in superoxide dismutase activity, and a decrease in oxidation protein products and thiobarbituric acid reactive substance concentrations.⁴⁷ However, one non-placebo-controlled trial suggests that regular daily white wine consumption could potentially lead to a pro-atherogenic increase in homocysteine concentrations.⁴⁸ There were, however, limitations in this study, such as the number of participants in each drinking pattern group (wine and beer drinkers). The difference in protective effect between red wines and white wines is perhaps due to the polyphenolic ratio. However, one study suggested that tyrosols (relatively unknown active compounds identified in white wines), along with known compounds such as caffeic acid, and shikimic acids, could potentially explain the biological mechanisms and association between white wine and cardiovascular disease.⁴⁹ Some studies suggested that wine acutely improves endothelial function in patients with coronary artery disease, and a moderate daily intake of white wine with dinner can have antioxidative and cardioprotective effects.^{50,51} However, there are also studies that

have reported no differences in the effects of red and white wines on endothelial function.⁵⁰ Further research is needed to compare directly between red wine and white wine consumption on cardiovascular disease effects. Methodology to stratify confounders (eg, subgroup analysis) or identify unknown confounders using machine learning is needed in alcohol research.

Liquor/Other Alcohol Consumption and Cardiovascular Outcomes

There is no study directly on liquor or distilled spirits and the associations with cardiovascular disease outcomes. Liquor or spirits such as gin and vodka do not have a significant number of polyphenols or other nonalcoholic compounds with purported cardiovascular benefits. Therefore, data are relatively limited. One longitudinal study indicated that the use of spirits at least once a week may be associated with a slightly reduced risk of acute myocardial infarction among coronary artery disease-free men aged 30-59 years, but has no impact on total mortality compared with men using less spirits.⁵² Several studies on spirit consumption and vascular risk found no J-shaped correlation.⁵³⁻⁵⁶ No statistically significant association with vascular events was apparent for the intake of spirits up to 60 g/d, which is the maximum dose investigated in the 10 studies included in this meta-analysis. Indeed, several studies noted that spirit consumption mostly occurred as binge drinking (defined as the consumption of 3 or more drinks within 1-2 hours) and was restricted to only a few days per week. This may explain the absence of association between moderate spirit consumption and cardiovascular disease benefit in the present review and in a previous study.⁵⁷ There are limited studies on the subtypes of liquor (whiskey, gin, rum, tequila) and cardiovascular disease. Researchers assessed whether consumption of 100 mL of whiskey or red wine by healthy male subjects increased plasma total phenol content and antioxidant capacity. They found that consumption of phenolic-containing alcoholic beverages transiently raised total phenol concentration and enhanced the antioxidant capacity of plasma.⁵⁸ This is compatible with suggestions that moderate alcohol usage and increased antioxidant intake decrease the risk of coronary heart disease.

Overall, although head-to-head comparisons between classes of alcoholic beverages are very limited, there may be underlying cardiovascular benefits from moderate alcohol consumption. However, further studies with confounder correction are needed to dissect this potential association before serious recommendations can be made. However, due to the many health risks linked to alcohol consumption (ie, dementia, alcohol use disorder, liver cirrhosis),²¹ no long-term randomized trials of alcohol consumption have been performed.⁵⁹

Limitations

There are significant limitations of the present study. Most meta-analyses fit linear models ignoring the J shape, or did

not use nondrinkers as the reference. First, the included studies are confounded by diet. For example, wine consumption is more often a component of the Mediterranean diet, while beer/liquor intake is more commonly accompanied by diets rich in oily and fried foods.^{60,61} Second, there is no genetic factor.⁶² A recent mendelian randomization study showed evidence of a causal relationship between higher alcohol consumption and an increased risk of stroke and peripheral artery disease.⁶³ The causal role of alcohol consumption for other cardiovascular diseases requires further research. Third, there is no drink pattern adjusted. Although some studies adjusted, the direction and magnitude of the effects of adjustment need to be further explored. Studies show that binge drinking is associated with increased coronary artery disease risk,⁶⁴ while alcohol is most cardioprotective when consumed prior to or during a meal.⁶⁵ For example, studies showed that wine drinkers who participated in this study reported a healthier diet than did drinkers of beer or spirits.^{66,67} Fourth, a lack of behavioral pattern adjustment is a limitation. For example, the Finnish study found that in their study population, men who drank spirits also regularly smoked.⁵² Fifth, most importantly, there were no adjustments for socioeconomic status. For example, a recent study suggested that coincident, favorable lifestyle factors attenuated the observational benefits of modest alcohol intake.⁶² Moreover, it is likely that any particular benefit of wine over beer and spirits is prone to confounding by diet and socioeconomic status.⁶⁶ Sixth, a limitation of many cohort studies is that they only have baseline estimates of alcohol intake, which may change over time. Finally, it is possible that the observational studies overestimate the benefits of alcohol for cardiovascular disease outcomes. Case-control and cross-sectional studies typically are more prone to bias and reverse causation. In fact, there is increasing concern about a greater risk of breast cancer and other cancers with even moderate alcohol intake. Further meta-analysis in alcohol and all-cause mortality is needed.

CONCLUSIONS

In individuals without liver disease, low to moderate amounts of weekly or daily alcohol consumption may be beneficial to cardiovascular health. Specifically, strong evidence has suggested that low-moderate amounts of weekly or daily red wine consumption may be particularly associated with low cardiovascular events. However, the relationship between alcohol consumption and cardiovascular disease appears to be biphasic and have a J-shape association. Heavy alcohol consumption could be harmful. Further prospective studies with correction of potential confounders (eg, lifestyle factors, socioeconomic status) are urgently needed. Further clinical trials, if able to be undertaken safely, are warranted to adequately determine the effect of alcohol consumption on cardiovascular disease.

ACKNOWLEDGMENTS

The authors would like to thank Dr. JoAnn E. Manson, MD, DrPH, MACP (Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Mass), Dr. Kenneth J. Mukamal, MD (Beth Israel Deaconess Medical Center, Harvard Medical School and Harvard TH Chan School of Public Health, Boston, Mass), and Dr. Meir Stampfer, MD, DrPH (Harvard T.H. Chan School of Public Health) for their suggestions and comments on this article.

References

1. United States Department of Agriculture. The Dietary Guidelines for Americans 2020-2025. Available at: https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary_Guidelines_for_Americans_2020-2025.pdf. Accessed April 8, 2022.
2. Ricci C, Schutte AE, Schutte R, Smits CM, Pieters M. Trends in alcohol consumption in relation to cause-specific and all-cause mortality in the United States: a report from the NHANES linked to the US mortality registry. *Am J Clin Nutr* 2020;111(3):580–9.
3. Arranz S, Chiva-Blanch M, Valdera-Martínez P, Medina-Remón A, Lamuela-Raventós RM, Estruch R. Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. *Nutrients* 2012;4(7):759–81.
4. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392(10159):1923–94.
5. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364(9438):937–52.
6. Gerhäuser C. Beer constituents as potential cancer chemopreventive agents. *Eur J Cancer* 2005;41(13):1941–54.
7. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health!. *Phytochemistry* 2004;65(10):1317–30.
8. Miranda CL, Stevens JF, Ivanov V, et al. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones in vitro. *J Agric Food Chem* 2000;48(9):3876–84.
9. Rodriguez RJ, Miranda CL, Stevens JF, Deiinger ML, Buhler DR. Influence of prenylated and non-prenylated flavonoids on liver microsomal lipid peroxidation and oxidative injury in rat hepatocytes. *Food Chem Toxicol* 2001;39(5):437–45.
10. Marcos A, Serra-Majem L, Pérez-Jiménez F, Pascual V, Tinahones FJ, Estruch R. Moderate consumption of beer and its effects on cardiovascular and metabolic health: an updated review of recent scientific evidence. *Nutrients* 2021;13(3):879.
11. Anastasius M, Kockx M, Jessup W, Sullivan D, Rye KA, Kritharides L. Cholesterol efflux capacity: an introduction for clinicians. *Am Heart J* 2016;180:54–63.
12. Davidson WS, Heink A, Sexmith H, et al. The effects of apolipoprotein B depletion on HDL subspecies composition and function. *J Lipid Res* 2016;57(4):674–86.
13. Hines LM, Rimm EB. Moderate alcohol consumption and coronary heart disease: a review. *Postgrad Med J* 2001;77(914):747–52.
14. Estruch R, Lamuela-Raventós RM. Wine, alcohol, polyphenols and cardiovascular disease. *Nutr Aging (Amst)* 2014;2(2-3):101–9.
15. Karatzi K, Rontoyanni VG, Protogerou AD, et al. Acute effects of beer on endothelial function and hemodynamics: a single-blind, crossover study in healthy volunteers. *Nutrition* 2013;29(9):1122–6.
16. Vilahur G, Casani L, Mendieta G, Lamuela-Riventos RM, Estruch R, Badimon L. Beer elicits vasculoprotective effects through Akt/eNOS activation. *Eur J Clin Invest* 2014;44(12):1177–88.

17. Milligan SR, Kalita JC, Pocock SR, et al. The endocrine activities of 8-prenylnaringenin and related hop (*Humulus lupulus L.*) flavonoids. *J Clin Endocrinol Metab* 2000;85(12):4912–5.
18. Stockley CS. The relationships between alcohol, wine and cardiovascular diseases – a review. *Nutr Aging (Amst)* 2015;3(2-4):55–88.
19. Padro T, Muñoz-García N, Vilahur G, et al. Moderate beer intake and cardiovascular health in overweight individuals. *Nutrients* 2018;10(9):1237.
20. Baliunas DO, Taylor BJ, Irving H, et al. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care* 2009;32(11):2123–32.
21. Roerecke M, Vafaie A, Hasan OSM, et al. Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. *Am J Gastroenterol* 2019;114(10):1574–86.
22. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. *Lancet* 1992;339(8808):1523–6.
23. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. *Circulation* 1993;88(6):2771–9.
24. Ferrières J. The French paradox: lessons for other countries. *Heart* 2004;90(1):107–11.
25. Waterhouse AL. Wine phenolics. *Ann N Y Acad Sci* 2002;957(1):21–36.
26. Chiva-Blanch G, Urpi-Sarda M, Llorach R, et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. *Am J Clin Nutr* 2012;95(2):326–34.
27. Chiva-Blanch G, Urpi-Sarda M, Ros E, et al. Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication. *Circ Res* 2012;111(8):1065–8.
28. Chiva-Blanch G, Urpi-Sarda M, Ros E, et al. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. *Clin Nutr* 2013;32(2):200–6.
29. Estruch R, Sacanella E, Badia E, et al. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial. Effects of wine on inflammatory markers. *Atherosclerosis* 2004;175(1):117–23.
30. Imhof A, Blagieva R, Marx N, Koenig W. Drinking modulates monocyte migration in healthy subjects: a randomised intervention study of water, ethanol, red wine and beer with or without alcohol. *Diab Vasc Dis Res* 2008;5(1):48–53.
31. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. *Lancet* 1979;1(8124):1017–20.
32. Janszky I, Ericson M, Blom M, et al. Wine drinking is associated with increased heart rate variability in women with coronary heart disease. *Heart* 2005;91(3):314–8.
33. Gepner Y, Golan R, Harman-Boehm I, et al. Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes: a 2-year randomized, controlled trial. *Ann Intern Med* 2015;163(8):569–79.
34. Markoski MM, Garavaglia J, Oliveira A, Olivaeas J, Marcadenti A. Molecular properties of red wine compounds and cardiometabolic benefits. *Nutr Metab Insights* 2016;9:51–7.
35. Huang P-H, Chen Y-H, Tsai H-Y, et al. Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. *Arterioscler Thromb Vasc Biol* 2010;30(4):869–77.
36. Corder R, Mullen W, Khan NQ, et al. Oenology: red wine procyanidins and vascular health. *Nature* 2006;444(7119):566.
37. Suo H, Tian R, Li J, et al. Compositional characterization study on high-molecular-mass polymeric polyphenols in red wines by chemical degradation. *Food Res Int* 2019;123:440–9.
38. Šeruga M, Novak I, Jakobek L. Determination of polyphenols content and antioxidant activity of some red wines by differential pulse voltammetry, HPLC and spectrophotometric methods. *Food Chemistry* 2011;124(3):1208–16.
39. Djoussé L, Lee IM, Buring JE, Gaziano JM. Alcohol consumption and risk of cardiovascular disease and death in women: potential mediating mechanisms. *Circulation* 2009;120(3):237–44.
40. Pavlidou E, Mantzourou M, Fasoulas A, Tryfonos C, Petridis D, Giaginis C. Wine: an aspiring agent in promoting longevity and preventing chronic diseases. *Diseases* 2018;6(3):73.
41. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. *Br J Nutr* 2011;106(3):383–9.
42. Estruch R, Sacanella E, Mota F, et al. Moderate consumption of red wine, but not gin, decreases erythrocyte superoxide dismutase activity: a randomised cross-over trial. *Nutr Metab Cardiovasc Dis* 2011;21(1):46–53.
43. Prasad K. Resveratrol, wine, and atherosclerosis. *Int J Angiol* 2012;21(1):7–18.
44. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. *Am J Clin Nutr* 1995;61(3):549–54.
45. Le Roy CI, Wells PM, Si J, Raes J, Bell JT, Spector TD. Red wine consumption associated with increased gut microbiota α -diversity in 3 independent cohorts. *Gastroenterology* 2020;158(1):270–272.e2.
46. Sacanella E, Vázquez-Agell M, Mena MP, et al. Down-regulation of adhesion molecules and other inflammatory biomarkers after moderate wine consumption in healthy women: a randomized trial. *Am J Clin Nutr* 2007;86(5):1463–9.
47. Micallef M, Lexis L, Lewandowski P. Red wine consumption increases antioxidant status and decreases oxidative stress in the circulation of both young and old humans. *Nutr J* 2007;6:27.
48. Roth I, Casas R, Medina-Remón A, Lamuela-Raventós RM, Estruch R. Consumption of aged white wine modulates cardiovascular risk factors via circulating endothelial progenitor cells and inflammatory biomarkers. *Clin Nutr* 2019;38(3):1036–44.
49. Bertelli AA. Wine, research and cardiovascular disease: instructions for use. *Atherosclerosis* 2007;195(2):242–7.
50. Whelan AP, Sutherland WHF, McCormick MP, Yeoman DJ, de Jong SA, Williams MJA. Effects of white and red wine on endothelial function in subjects with coronary artery disease. *Intern Med J* 2004;34(5):224–8.
51. Rajdl D, Racek J, Trefil J, Siala K. Effect of white wine consumption on oxidative stress markers and homocysteine levels. *Physiol Res* 2007;56(2):203–12.
52. Salonen JT, Puska P, Nissinen A. Intake of spirits and beer and risk of myocardial infarction and death—a longitudinal study in Eastern Finland. *J Chronic Dis* 1983;36(7):533–43.
53. Yano K, Rhoads GG, Kagan A. Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. *N Engl J Med* 1977;297(8):405–9.
54. Grønbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. *Ann Intern Med* 2000;133(6):411–9.
55. Malarcher AM, Giles WH, Croft JB, et al. Alcohol intake, type of beverage, and the risk of cerebral infarction in young women. *Stroke* 2001;32(1):77–83.
56. Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. *N Engl J Med* 2003;348(2):109–18.
57. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. *BMJ* 1996;312(7033):731–6.
58. Duthie GG, Pedersen MW, Gardner PT, et al. The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. *Eur J Clin Nutr* 1998;52(10):733–6.

59. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. *JAMA* 2018;320(8):815–24.
60. Senoner T, Dichtl W. Oxidative stress in cardiovascular diseases: still a therapeutic target? *Nutrients* 2019;11(9):2090.
61. Haseeb S, Alexander B, Baranchuk A. Wine and cardiovascular health. *Circulation* 2017;136(15):1434–48.
62. Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. *JAMA Netw Open* 2022;5(3):e223849.
63. Larsson SC, Burgess S, Mason AM, Michaëlsson K. Alcohol consumption and cardiovascular disease: a mendelian randomization study. *Circ Genom Precis Med* 2020;13(3):e002814.
64. Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, de Gaetano G. Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease. *Circulation* 2010;121(17):1951–9.
65. Rehm J, Sempos CT, Trevisan M. Alcohol and cardiovascular disease—more than one paradox to consider. Average volume of alcohol consumption, patterns of drinking and risk of coronary heart disease—a review. *J Cardiovasc Risk* 2003;10(1):15–20.
66. Tjønneland A, Grønbaek M, Stripp C, Overvad K. Wine intake and diet in a random sample of 48763 Danish men and women. *Am J Clin Nutr* 1999;69(1):49–54.
67. Klatsky AL. Moderate drinking and reduced risk of heart disease. *Alcohol Res Health* 1999;23(1):15–23.
68. Bos Sarah, Grobbee Diederick E, Boer Jolanda M A, Monique Verschuren W, Beulens Joline W J. Alcohol consumption and risk of cardiovascular disease among hypertensive women. *European journal of cardiovascular prevention and rehabilitation* 1 February 2010;17(1):119–26.
69. Brenner Hermann, Rothenbacher Dietrich, Bode Günter, März Winfried, Hoffmeister Albrecht, Koenig Wolfgang. Coronary Heart Disease Risk Reduction in a Predominantly Beer-Drinking Population. *Epidemiology* July 2001;12(4):390–5.
70. Foerster M, Marques-Vidal P, Gmel G, Daepfen JB, Cornuz J, Hayoz D, Pécoud A, Mooser V, Waeber G, Vollenweider P, Paccaud F, Rodondi N. Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. *Am J Cardiol* 2009;103(3):361–8.
71. Gigleux I, Gagnon J, St-Pierre A, Cantin B, Dagenais GR, Meyer F, Després JP, Lamarche B. Moderate alcohol consumption is more cardioprotective in men with the metabolic syndrome. *J Nutr* 2006;136(12):3027–32.
72. Klatsky AL, Armstrong MA, Friedman GD. Relations of alcoholic beverage use to subsequent coronary artery disease hospitalization. *Am J Cardiol* 1986;58(9):710–4.
73. Klatsky AL, Armstrong MA, Friedman GD. Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization. *Am J Cardiol* 1997;80(4):416–20.
74. Marques-Vidal P, Montaye M, Arveiler D, Evans A, Bingham A, Ruidavets JB, Amouyel P, Haas B, Yarnell J, Ducimetière P, Ferrières J. Alcohol consumption and cardiovascular disease: differential effects in France and Northern Ireland. The PRIME study. *Eur J Cardiovasc Prev Rehabil* 2004;11(4):336–43.
75. Park JE, Ryu Y, Cho SI. The Effect of Reference Group Classification and Change in Alcohol Consumption on the Association Between Alcohol Consumption and Cardiovascular Disease. *Alcohol Clin Exp Res* 2017;41(2):379–87.
76. Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, Stampfer MJ. Prospective study of alcohol consumption and risk of coronary disease in men. *Lancet* 1991 Aug 24;338(8765):464–8.
77. Stampfer MJ, Colditz GA, Willett WC, Speizer FE, Hennekens CH. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. *N Engl J Med* 1988;319(5):267–73.
78. Wannamethee SG, Shaper AG. Type of alcoholic drink and risk of major coronary heart disease events and all-cause mortality. *Am J Public Health* 1999;89(5):685–90.
79. Wellmann J, Heidrich J, Berger K, Döring A, Heuschmann PU, Keil U. Changes in alcohol intake and risk of coronary heart disease and all-cause mortality in the MONICA/KORA-Augsburg cohort 1987–97. *Eur J Cardiovasc Prev Rehabil* 2004;11(1):48–55.
80. Woodward M, Tunstall-Pedoe H. Alcohol consumption, diet, coronary risk factors, and prevalent coronary heart disease in men and women in the Scottish heart health study. *J Epidemiol Community Health* 1995;49(4):354–62.
81. Keil U, Chambless LE, Döring A, Filipiak B, Stieber J. The relation of alcohol intake to coronary heart disease and all-cause mortality in a beer-drinking population. *Epidemiology* 1997;8(2):150–6.
82. Biddinger KJ, Emdin CA, Haas ME, Wang M, Hindy G, Ellinor PT, Kathiresan S, Khera AV, Aragam KG. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. *JAMA Netw Open* 2022;5(3):e223849.
83. Behrens G, Leitzmann MF, Sandin S, Löf M, Heid IM, Adami HO, Weiderpass E. The association between alcohol consumption and mortality: the Swedish women’s lifestyle and health study. *Eur J Epidemiol* 2011;26(2):81–90.
84. Berberian KM, van Duijn CM, Hoes AW, et al. Alcohol and mortality. *Eur J Epidemiol* 1994;10:587–93.
85. Bertoia Monica L, et al. Long-term alcohol and caffeine intake and risk of sudden cardiac death in women. *The American journal of clinical nutrition* 2013;97(6):1356–63.
86. Dai J, Mukamal KJ, Krasnow RE, Swan GE, Reed T. Higher usual alcohol consumption was associated with a lower 41-y mortality risk from coronary artery disease in men independent of genetic and common environmental factors: the prospective NHLBI Twin Study. *Am J Clin Nutr* 2015;102(1):31–9.
87. Deev A, Shestov D, Abernathy J, Kapustina A, Muhina N, Irving S. Association of alcohol consumption to morality in middle-aged U.S. and Russian men and women. *Ann Epidemiol* 1998;8(3):147–53.
88. Diem P, Deplazes M, Fajfr R, Bearth A, Müller B, Christ ER, Teuscher A. Effects of alcohol consumption on mortality in patients with Type 2 diabetes mellitus. *Diabetologia* 2003;46(11):1581–5.
89. Grabas MP, Hansen SM, Torp-Pedersen C, Bøggild H, Ullits LR, Deding U, Nielsen BJ, Jensen PF, Overgaard C. Alcohol consumption and mortality in patients undergoing coronary artery bypass graft (CABG)-a register-based cohort study. *BMC Cardiovasc Disord* 2016;16(1):219.
90. Harriss LR, English DR, Hopper JL, Powles J, Simpson JA, O’Dea K, Giles GG, Tonkin AM. Alcohol consumption and cardiovascular mortality accounting for possible misclassification of intake: 11-year follow-up of the Melbourne Collaborative Cohort Study. *Addiction* 2007;102(10):1574–85.
91. Hernandez-Hernandez A, Gea A, Ruiz-Canela M, Toledo E, Beunza JJ, Bes-Rastrollo M, Martinez-Gonzalez MA. Mediterranean Alcohol-Drinking Pattern and the Incidence of Cardiovascular Disease and Cardiovascular Mortality: The SUN Project. *Nutrients* 2015;7(11):9116–26.
92. Hoffmeister H, Schelp FP, Mensink GB, Dietz E, Böhning D. The relationship between alcohol consumption, health indicators and mortality in the German population. *Int J Epidemiol* 1999;28(6):1066–72.
93. Kauhanen Jussi, et al. Frequent Hangovers and Cardiovascular Mortality in Middle-Aged Men. *Epidemiology* 1997;8(3):310–4 . JSTOR <http://www.jstor.org/stable/3702259> Accessed 9 Jun. 2022.
94. Laatikainen T, Manninen L, Poikolainen K, Vartiainen E. Increased mortality related to heavy alcohol intake pattern. *J Epidemiol Community Health* 2003;57(5):379–84.
95. Mukamal KJ, Chen CM, Rao SR, Breslow RA. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. *J Am Coll Cardiol* 2010;55(13):1328–35.
96. Malyutina S, Bobak M, Kurilovitch S, Gafarov V, Simonova G, Nikitin Y, Marmot M. Relation between heavy and binge drinking and all-cause and cardiovascular mortality in Novosibirsk, Russia: a prospective cohort study. *Lancet* 2002;360(9344):1448–54.

97. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Prior alcohol consumption and mortality following acute myocardial infarction. *JAMA* 2001;285(15):1965–70.
98. Pai JK, Mukamal KJ, Rimm EB. Long-Term Alcohol Consumption in Relation to All-Cause and Cardiovascular Mortality among Survivors of Myocardial Infarction: The Health Professionals Follow-up Study. *European Heart Journal* 2012;33(13):1598–605.
99. Roy A, Prabhakaran D, Jeemon P, Thankappan KR, Mohan V, Ramakrishnan L, Joshi P, Ahmed F, Mohan BV, Saran RK, Sinha N, Reddy KS. Sentinel Surveillance in Industrial Populations Study Group. Impact of alcohol on coronary heart disease in Indian men. *Atherosclerosis* 2010;210(2):531–5.
100. Snow WM, Murray R, Ekuma O, Tyas SL, Barnes GE. Alcohol use and cardiovascular health outcomes: a comparison across age and gender in the Winnipeg Health and Drinking Survey Cohort. *Age Ageing* 2009;38(2):206–12.
101. Song Rebecca J, et al. Alcohol Consumption and Risk of Coronary Artery Disease (from the Million Veteran Program). *The American journal of cardiology* 2018;121(10):1162–8.
102. Suadicani P, Hein HO, Gyntelberg F. Wine intake, ABO phenotype, and risk of ischemic heart disease and all-cause mortality: the Copenhagen Male Study—a 16-year follow-up. *Alcohol* 2008;42(7):575–82.
103. Hart CL, Smith GD, Hole DJ, Hawthorne VM. Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: results from a prospective cohort study of scottish men with 21 years of follow up. *BMJ* 1999;318(7200):1725–9.
104. Yuan JM, Ross RK, Gao YT, Henderson BE, Yu MC. Follow up study of moderate alcohol intake and mortality among middle aged men in Shanghai, China. *BMJ*. 1997;4;(314):18–23.
105. Waskiewicz A, Sygnowska E, Drygas W. Relationship between alcohol consumption and cardiovascular mortality—the Warsaw POLMONICA Project. *Kardiol Pol* 2004;60(6):552–62.
106. Tverdal A, Magnus P, Selmer R, Thelle D. Consumption of alcohol and cardiovascular disease mortality: a 16 year follow-up of 115,592 Norwegian men and women aged 40–44 years. *Eur J Epidemiol* 2017;32(9):775–83.
107. Trevisan M, Schisterman E, Mennotti A, Farchi G, Conti S. Risk Factor And Life Expectancy Research Group. Drinking pattern and mortality: the Italian Risk Factor and Life Expectancy pooling project. *Ann Epidemiol* 2001;11(5):312–9.
108. Theobald H, Bygren LO, Carstensen J, Engfeldt P. A moderate intake of wine is associated with reduced total mortality and reduced mortality from cardiovascular disease. *J Stud Alcohol* 2000;61(5):652–6.
109. Suhonen O, Aromaa A, Reunanen A, Knekt P. Alcohol consumption and sudden coronary death in middle-aged Finnish men. *Acta Med Scand* 1987;221(4):335–41.
110. Streppel MT, Ocké MC, Boshuizen HC, Kok FJ, Kromhout D. Long-term wine consumption is related to cardiovascular mortality and life expectancy independently of moderate alcohol intake: the Zutphen Study. *J Epidemiol Community Health* 2009;63(7):534–40.
111. Schutte R, Papageorgiou M, Najlah M, Huisman HW, Ricci C, Zhang J, Milner N, Schutte AE. Drink types unmask the health risks associated with alcohol intake - Prospective evidence from the general population. *Clin Nutr* 2020 Oct;39(10):3168–74.
112. Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, Stampfer MJ. Prospective study of alcohol consumption and risk of coronary disease in men. *Lancet* 1991;338(8765):464–8.
113. Renaud SC, Guéguen R, Schenker J, d’Houtaud A. Alcohol and mortality in middle-aged men from eastern France. *Epidemiology* 1998;9(2):184–8.
114. Renaud SC, Guéguen R, Conard P, Lanzmann-Petithory D, Orgogozo JM, Henry O. Moderate wine drinkers have lower hypertension-related mortality: a prospective cohort study in French men. *Am J Clin Nutr* 2004;80(3):621–5.

Funding: None.

Conflicts of Interest: Dr. Krittanawong discloses the following relationships – Member of the American College of Cardiology Solution Set Oversight Committee, the American Heart Association Committee of the Council on Genomic and Precision Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Performance Measures, The Lancet Digital Health (Advisory Board), European Heart Journal Digital Health (Editorial board), Journal of the American Heart Association (Editorial board), JACC: Asia (Section Editor), The Journal of Scientific Innovation in Medicine (Associate Editor), and Frontiers in Cardiovascular Medicine (Associate Editor). Dr. Rose-son receives research funding to his institution from Amgen, Arrowhead, Lilly, NIH, Novartis, Regeneron; consulting fees from Amgen, Lilly, Novartis, Regeneron, non-promotional speaking fees from Amgen, Kowa; royalties from Wolters Kluwer for UpToDate, and has stock holdings in MediMergent LLC. Dr. Virani discloses the following Grant support: Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family. Honorarium: American College of Cardiology (Associate Editor for Innovations, ACC.org). Steering Committee: Patient and Provider Assessment of Lipid Management (PALM) registry at Duke Clinical Research Institute (no financial remuneration). Dr. Qi is supported by grants from the National Heart, Lung, and Blood Institute (HL071981, HL034594, HL126024), the National Institute of Diabetes and Digestive and Kidney Diseases (DK115679, DK091718, DK100383, DK078616), the Fogarty International Center (TW010790), Tulane Research Centers of Excellence Awards. Dr. Qi is also supported by P30DK072476 and NIGMS P20GM109036. Dr. Long is supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases K23 DK113252, the Doris Duke Charitable Foundation Grant #2019085, Gilead Sciences Research Scholars Award, Echosens Corporation, the Boston University. Dr. Tangney is an UpToDate consultant. Other authors have no disclosure.

Authorship: All authors had access to the data, contributed significantly to the work and a role in writing the manuscript.

SUPPLEMENTARY DATA

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.amjmed.2022.04.021>.

SUPPLEMENTARY MATERIAL**eMethods:** Search Strategies

No restrictions were placed on language or publication date. Search strategy included MESH headings and keywords including “alcohol,” “alcohol consumption,” “cardiovascular disease,” “cardiovascular events,” “diabetes,” “hypertension,” “high blood pressure,” “hyperlipidemia,” “dyslipidemia,” “arrhythmia,” “coronary artery disease,” “ischemic heart disease,” “acute myocardial infarct,” “acute coronary syndrome,” “stroke,” “heart failure,” “cardiac failure,” “cardiac insufficiency,” and “cardiomyopathy.” We identified studies based on appropriate types of study (observational study, prospective cohort study, randomized controlled trial, or case control design) and the exposure (alcohol consumption). We excluded animal studies, editorials, and reviews. Two investigators independently reviewed abstracts for potentially eligible studies. Full text reports were then assessed for eligibility and disagreements were resolved by consensus discussion. We were unable to perform meta-analysis of the results due to tremendous heterogeneity among the included studies related to intervention, comparison, outcomes, and timing. Instead, we qualitatively synthesized the results and summarized key features and characteristics (eg, study populations, design, interventions, outcomes, and conclusions) of the included studies.

Cochrane searches

Search	PubMed Terms	Results
S1: alcohol (all types)		
S2: cardiovascular diseases	TOPIC: ("Cardiovascular Diseases" OR arrhythmia* OR "Atrial Fibrillation" OR "Atrial Flutter" OR "Bradycardia" OR "Tachycardia" OR "Ventricular Fibrillation" OR "heart failure" OR "cardiac failure" OR "myocardial failure" OR "cardiac insufficiency" OR cardiomyopath* OR myocarditis OR stroke* OR "cardiac arrest" OR "Cardiopulmonary Arrest" OR asystole* OR "sudden cardiac death" OR "cardiovascular disease" OR "Cardiovascular Diseases" OR "Heart Diseases" OR "Heart Disease" OR "coronary heart disease" OR "coronary heart diseases" OR "coronary disease" OR "coronary diseases" OR "coronary artery disease" OR "ischemic heart disease" OR "ischaemic heart disease" OR "Myocardial Ischemia" OR "Myocardial Ischemias" OR "Myocardial Ischaemia" OR "Myocardial Ischaemias" OR "acute coronary syndrome" OR "myocardial infarction" OR "myocardial infarct" OR "heart attack" OR "heart attacks" OR "cardiovascular events" OR "cardiovascular event")	1,519,764
S3: beer	TS=(beer*)	27,406
S4: red wine	TS=("red wine" OR "red wines" OR (red NEAR/3 wine))	13,947
S5: white wine	TS=("white wine" OR "white wines" OR (white NEAR/3 wine))	4533
S6: all wine		
S7: all alcohols + CVD	S1 AND S2	
S8: beer + CVD	S2 AND S3	801
S9: red wine + CVD	S2 AND S4	1913
S10: white wine + CVD	S2 AND S5	198
S11: all wine + CVD – red, white, not specified	S2 AND S6	
S12: “other” alcohol + CVD – those not returned in S8, S9, S10 or S11	S7 NOT S3 NOT S4 NOT S5 NOT S6	
S13: resveratrol	S2 AND resveratrol	

CVD = cardiovascular disease

Embase searches

Search	PubMed Terms	Results(link to PubMed)
S1: alcohol (all types)		
S2: cardiovascular diseases	'cardiovascular disease'/exp OR arrhythmia*:ab,ti,kw OR 'atrial fibrillation':ab,ti,kw OR 'atrial flutter':ab,ti,kw OR 'bradycardia':ab,ti,kw OR 'tachycardia':ab,ti,kw OR 'ventricular fibrillation':ab,ti,kw OR 'heart failure':ab,ti,kw OR 'cardiac failure':ab,ti,kw OR 'myocardial failure':ab,ti,kw OR 'cardiac insufficiency':ab,ti,kw OR cardiomyopath*:ab,ti,kw OR myocarditis:ab,ti,kw OR stroke*:ab,ti,kw OR 'cardiac arrest':ab,ti,kw OR 'heart arrest':ab,ti,kw OR 'cardiopulmonary arrest':ab,ti,kw OR asystole*:ab,ti,kw OR 'sudden cardiac death':ab,ti,kw OR 'cardiovascular disease':ab,ti,kw OR 'cardiovascular diseases':ab,ti,kw OR 'heart diseases':ab,ti,kw OR 'heart disease':ab,ti,kw OR 'coronary disease':ab,ti,kw OR 'coronary diseases':ab,ti,kw OR 'coronary artery disease':ab,ti,kw OR 'myocardial ischemia':ab,ti,kw OR 'myocardial ischemias':ab,ti,kw OR 'myocardial ischaemia':ab,ti,kw OR 'myocardial ischaemias':ab,ti,kw OR 'acute coronary syndrome':ab,ti,kw OR 'myocardial infarction':ab,ti,kw OR 'myocardial infarct':ab,ti,kw OR 'heart attack':ab,ti,kw OR 'heart attacks':ab,ti,kw OR 'heart infarction':ab,ti,kw OR 'heart infarct':ab,ti,kw OR 'cardiovascular events':ab,ti,kw OR 'cardiovascular event':ab,ti,kw	4,834,122
S3: beer	'beer'/exp OR beer:ti,ab,kw OR beers:ti,ab,kw	16,020
S4: red wine	'red wine'/exp OR 'red wine':ti,ab,kw OR 'red wines':ti,ab,kw OR ((red NEXT/3 wine):ti,ab,kw) OR ((red NEXT/3 wines):ti,ab,kw)	6862
S5: white wine	'white wine'/exp OR 'white wine':ti,ab,kw OR 'white wines':ti,ab,kw OR ((white NEXT/3 wine):ti,ab,kw) OR ((white NEXT/3 wines):ti,ab,kw)	1904
S8: beer + CVD	S2 AND S3	1515
S9: red wine + CVD	S2 AND S4	1665
S10: white wine + CVD	S2 AND S5	184

CVD = cardiovascular disease.

PubMed Searches

Search	PubMed Terms	Results(link to PubMed)
S1: alcohol (all types)	alcohol drinking OR wine OR wines OR beer[tw] OR beers[tw] OR ethanol OR alcoholic beverages	286,810
S2: cardiovascular diseases	("Cardiovascular Diseases"[mh] OR arrhythmia*[tw] OR "Atrial Fibrillation"[tw] OR "Atrial Flutter"[tw] OR "Bradycardia"[tw] OR "Tachycardia"[tw] OR "Ventricular Fibrillation"[tw] OR "heart failure"[tw] OR "cardiac failure"[tw] OR "myocardial failure"[tw] OR "cardiac insufficiency"[tw] OR cardiomyopath*[tw] OR myocarditis[tw] OR stroke*[tw] OR "cardiac arrest"[tw] OR "Cardiopulmonary Arrest"[tw] OR asystole*[tw] OR "sudden cardiac death"[tw] OR "cardiovascular disease"[tw] OR "Cardiovascular Diseases"[tw] OR "Heart Diseases"[tw] OR "Heart Disease"[tw] OR "coronary heart disease"[tw] OR "coronary heart diseases"[tw] OR "coronary disease"[tw] OR "coronary diseases"[tw] OR "coronary artery disease"[tw] OR "ischemic heart disease"[tw] OR "ischaemic heart disease"[tw] OR "Myocardial Ischemia"[tw] OR "Myocardial Ischemias"[tw] OR "Myocardial Ischaemia"[tw] OR "Myocardial Ischaemias"[tw] OR "acute coronary syndrome"[tw] OR "myocardial infarction"[tw] OR "myocardial infarct"[tw] OR "heart attack"[tw] OR "heart attacks"[tw] OR "cardiovascular events"[tw] OR "cardiovascular event"[tw])	2,756,209
S3: beer	beer[tw] OR beers[tw]	10,963
S4: red wine	"red wine"[tw] OR "red wines"[tw] OR (red AND "white wine") OR (red AND "white wines")	4992
S5: white wine	"white wine"[tw] OR "white wines"[tw] OR (white AND "red wine") OR (white AND "red wines")	1553
S6: all wine	wine[tw] OR wines[tw] S1 AND S2	21,600 17,481

(Continued)

Search	PubMed Terms	Results(link to PubMed)
S7: all alcohols + CVD		
S8: beer + CVD	S2 AND S3	704
S9: red wine + CVD	S2 AND S4	897
S10: white wine + CVD	S2 AND S5	109
S11: all wine + CVD – red, white, not specified	S2 AND S6	2300
S12: “other” alcohol + CVD – those not returned in S8, S9, S10 or S11	S7 NOT S3 NOT S4 NOT S5 NOT S6	14,780
S13: resveratrol	S2 AND resveratrol	1692

CVD = cardiovascular disease

Web of Science searches

Search	PubMed Terms	Results
S1: alcohol (all types)		
S2: cardiovascular diseases	TOPIC: ("Cardiovascular Diseases" OR arrhythmia* OR "Atrial Fibrillation" OR "Atrial Flutter" OR "Bradycardia" OR "Tachycardia" OR "Ventricular Fibrillation" OR "heart failure" OR "cardiac failure" OR "myocardial failure" OR "cardiac insufficiency" OR cardiomyopath* OR myocarditis OR stroke* OR "cardiac arrest" OR "Cardiopulmonary Arrest" OR asystole* OR "sudden cardiac death" OR "cardiovascular disease" OR "Cardiovascular Diseases" OR "Heart Diseases" OR "Heart Disease" OR "coronary heart disease" OR "coronary heart diseases" OR "coronary disease" OR "coronary diseases" OR "coronary artery disease" OR "ischemic heart disease" OR "ischaemic heart disease" OR "Myocardial Ischemia" OR "Myocardial Ischemias" OR "Myocardial Ischaemia" OR "Myocardial Ischaemias" OR "acute coronary syndrome" OR "myocardial infarction" OR "myocardial infarct" OR "heart attack" OR "heart attacks" OR "cardiovascular events" OR "cardiovascular event")	1,519,764
S3: beer	TS=(beer*)	27,406
S4: red wine	TS=("red wine" OR "red wines" OR (red NEAR/3 wine))	13,947
S5: white wine	TS=("white wine" OR "white wines" OR (white NEAR/3 wine))	4533
S6: all wine		
S7: all alcohols + CVD		
S8: beer + CVD	S1 AND S2	801
S9: red wine + CVD	S2 AND S3	1913
S10: white wine + CVD	S2 AND S4	198
S11: all wine + CVD – red, white, not specified	S2 AND S5	
S12: “other” alcohol + CVD – those not returned in S8, S9, S10 or S11	S2 AND S6	
S13: resveratrol	S7 NOT S3 NOT S4 NOT S5 NOT S6	
S13: resveratrol	S2 AND resveratrol	

CVD = cardiovascular disease